- President Trump’s aggressive executive order aims to eliminate pharmacy benefit managers (PBMs) and align U.S. drug prices with international levels.
- Shares of CVS, Cigna, and UnitedHealth tumbled as investors digested the regulatory blow to the PBM business model.
- Trump’s move targets drug price transparency by cutting out aggressive intermediaries blamed for inflated costs.
Trump Targets PBMs with Aggressive Executive Order
In a move that sent shockwaves through the healthcare sector, former President Donald Trump on Monday signed an aggressive executive order aimed at eliminating the role of pharmacy benefit managers (PBMs) in U.S. drug pricing. The order is part of a broader initiative to reduce domestic prescription drug costs by aligning them with the “most favored nation” prices offered in other developed countries.
“We’re going to cut out the middlemen and facilitate the direct sale of drugs at the most favored nation price, directly to the American citizen,” Trump said during a press conference.
The U.S. currently pays up to three times more for medications than other nations, and this executive order seeks to reduce that disparity by creating mechanisms for patients to purchase drugs directly from manufacturers.
Aggressive Market Reaction Hits PBM Giants
Wall Street reacted swiftly to the announcement, especially to the order’s language on bypassing private-sector intermediaries.
- CVS Health (Caremark): Down 5%
- Cigna (Express Scripts): Down 6%
- UnitedHealth Group (OptumRx): Down 0.5%
By directly challenging the PBM business model, Trump’s aggressive approach triggered investor anxiety about the long-term viability of companies that rely heavily on negotiating rebates and managing prescription drug plans.
Gabelli Funds portfolio manager Jeff Jonas commented, “The system of high list prices and big, hidden rebates makes the system very opaque and hard to navigate. The executive order will keep that negative pressure on companies like Cigna, CVS, and UnitedHealth.”
PBMs in the Crosshairs of Aggressive Reform
PBMs have already faced regulatory scrutiny from the Federal Trade Commission under the Biden administration, particularly for insulin pricing practices. These intermediaries have been accused of contributing to high drug costs by negotiating significant rebates from manufacturers while failing to pass the savings on to patients.
Industry critics argue that PBMs thrive in a non-transparent pricing environment. Trump’s aggressive policy aims to introduce price clarity by dismantling a system that many blame for inflating healthcare costs.
“The aftermarket discounts and fees PBMs demand add hidden costs to drug prices,” noted healthcare analysts.
Despite the criticism, PBMs argue they play a crucial role in holding pharmaceutical companies accountable. Greg Lopes, spokesperson for the Pharmaceutical Care Management Association, stated, “PBMs are the only check against drug companies’ unlimited pricing power.”
CVS Responds to Aggressive Order with Cautious Optimism
CVS Health, one of the largest operators of PBMs, issued a carefully worded response to Trump’s executive order. A spokesperson said the company “welcomed the president’s focus on pricing by pharmaceutical companies” and expressed interest in discussions to enhance affordability.
Interestingly, CVS highlighted that its negotiations under Medicare prescription drug plans had delivered significantly lower costs than the direct government negotiations for top-selling drugs under the Inflation Reduction Act. This underscores the complexity of the issue, and whether cutting out PBMs will indeed lower prices remains contested.
Implementation Challenges Despite Aggressive Intent
While Trump’s executive order is aggressive in tone and ambition, experts warn that implementation may not be straightforward. One major obstacle is the American reliance on employer-sponsored health insurance, which may not be fully compatible with a government-facilitated direct purchasing model.
Moreover, analysts suggest congressional oversight may be required to enforce any sweeping changes, especially if legal challenges arise from impacted PBM operators or pharmaceutical companies.
Conclusion: An Aggressive Gamble with High Stakes
Trump’s executive order marks an aggressive attempt to overhaul the complex and often-criticized U.S. drug pricing system. While it may succeed in cutting costs for consumers, the near-term impact on healthcare stocks and the uncertainty around enforcement make it one of the most controversial drug pricing reforms to date.
For now, the executive order leaves the pharmaceutical landscape in flux—rattling investors, alarming PBMs, and raising questions about how to balance transparency, affordability, and access in the American healthcare system.
For Best Business, Finance and Market Insights, stay tuned to Global Finserve
Watch Latest Business Videos
Latest Global Market Trend